Skip to main navigation
Skip to search
Skip to main content
Scholars @ UT Health San Antonio Home
Help & FAQ
English
Español
Home
Profiles
Research units
Publications
Datasets
Search by expertise, name or affiliation
Profile of lebrikizumab and its potential in the treatment of asthma
Diego Jose Maselli
,
Holly Keyt
, Linda Rogers
Division of Pulmonary Diseases
Division of Pulmonary Medicine
Lung Transplant
Research output
:
Contribution to journal
›
Review article
›
peer-review
20
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Profile of lebrikizumab and its potential in the treatment of asthma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Interleukin 13
100%
Combination Therapy
60%
Asthma
60%
Transcription Factor RUNX2
40%
Disease Marker
40%
Treatment of Asthma
40%
Receptor
20%
Protein
20%
Monoclonal Antibody
20%
Cell Type
20%
Serositis
20%
Mediator
20%
Fibrosis
20%
Immunoglobulin E
20%
Interleukin 4
20%
Airway Remodeling
20%
Patient
20%
T-Helper Cell
20%
Lung Function
20%
Eosinophil
20%
Immunology and Microbiology
Asthma
100%
Interleukin 13
100%
Lebrikizumab
80%
Transcription Factor RUNX2
40%
Monoclonal Antibodies
20%
Immunoglobulin E
20%
Mediator
20%
Interleukin 4
20%
T Helper Cell
20%
Eosinophil Count
20%
Electric Potential
20%
Inflammation
20%
Lung Function
20%
Pharmacology, Toxicology and Pharmaceutical Science
Interleukin 13
100%
Lebrikizumab
80%
Asthma
60%
Disease Marker
40%
Transcription Factor RUNX2
40%
Receptor
20%
Protein
20%
Monoclonal Antibody
20%
Fibrosis
20%
Immunoglobulin E
20%
Interleukin 4
20%
Airway Remodeling
20%